124070-15-1|ADCI|10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene-5-carboxamide|-范德生物科技公司

ADCI

NMR下载 COA and HPLC MSDS下载
names：
10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene-5-carboxamide
CAS号：
124070-15-1
MDL Number：
MF(分子式)： C16H14N2O MW(分子量)： 250.301
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	ADCI
英文别名	ADCI; SGB-017; SGB017; SGB 017
CAS号	124070-15-1
SMILES	O=C(C1(N2)C3=CC=CC=C3CC2C4=CC=CC=C14)N
Inchi	InChI=1S/C16H14N2O/c17-15(19)16-12-7-3-1-5-10(12)9-14(18-16)11-6-2-4-8-13(11)16/h1-8,14,18H,9H2,(H2,17,19)
InchiKey	IFLVGRRVGPXYON-UHFFFAOYSA-N
分子式 Formula	C16H14N2O
分子量 Molecular Weight	250.301
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	ADCI(CAS:124070-15-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	ADCI, also known as SGB-017, is a glutamate receptor antagonist potentially for the treatment of epilepsy. ADCI blocks both voltage-activated sodium channels and N-methyl-D-aspartate (NMDA)-receptor-gated channels. Inhibition of sodium channels by ADCI was voltage dependent. High doses of ADCI increased dopamine metabolism in the prefrontal cortex and/or in the nucleus accumbens, but not in the dorsal striatum.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Sun L, Lin SS. The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70. PubMed PMID: 10714396.

[2]Geter-Douglass B, Witkin JM. Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology (Berl). 1999 Oct;146(3):280-9. PubMed PMID: 10541728.

[3] Bubser M, Zadow B, Kronthaler UO, Felsheim U, Rückert NG, Schmidt WJ. Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):767-73. PubMed PMID: 9205962.

[4] Grant KA, Colombo G, Grant J, Rogawski MA. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology. 1996;35(12):1709-19. PubMed PMID: 9076750.

[5] Rogawski MA, Le DQ, Uyakul D, Pannell LK, Subramaniam S, Yamaguchi S, Kokate TG. Anticonvulsant efficacy of ADCI (5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia. 1995 Jun;36(6):566-71. PubMed PMID: 7555968.

6: Seidleck BK, Thurkauf A, Witkin JM. Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: comparison with the structural analogs dizocilpine and carbamazepine. Pharmacol Biochem Behav. 1994 Apr;47(4):839-44. PubMed PMID: 8029253.7: Grant KA, Snell LD, Rogawski MA, Thurkauf A, Tabakoff B. Comparison of the effects of the uncompetitive N-methyl-D-aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine (ADCI) with its structural analogs dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizures. J Pharmacol Exp Ther. 1992 Mar;260(3):1017-22. PubMed PMID: 1545374.8: Rogawski MA, Yamaguchi S, Jones SM, Rice KC, Thurkauf A, Monn JA. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D- aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10-imine (ADCI): comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. J Pharmacol Exp Ther. 1991 Oct;259(1):30-7. PubMed PMID: 1920122.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开